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Because the value of monitoring amiodarone plasma con-
centrations remains undefined, this study was performed
to evaluate its role during the management of patients
receiving amiodarone. The early electrophysiologic ef-
fects of amiodarone were assessed in 40 consecutive pa-
tients with coronary artery disease and sustained ven-
tricular tachycardia or fibrillation who underwent
electrophysiologic studies and measurement of amio-
darone plasma concentration before and 29 ± 15
(mean ± SD) days after initiation of therapy. Amio-
darone and desethylamiodarone plasma levels did not
correlate with changes in either sinus cycle length, QTc
interval, ventricular effective refractory period, AH and
HV intervals or ventricular tachycardia cycle length.
Amiodarone and desethylamiodarone plasma concen-
trations and the effects of the drug on conduction inter-
valsor right ventricular effectiverefractory periods were
not related to suppression of arrhythmia induction by
ventricular stimulation after 1 month of therapy.
The relation between amiodarone plasma concentra-
tions and both toxicity and efficacy during long-term
therapy were prospectively assessed in a larger series of
114 consecutive patients with either symptomatic supra-
ventricular or ventricular arrhythmias who were fol-
Amiodarone is a potent antiarrhythmic agent with demon-
strated activity against supraventricular and ventricular ar-
rhythmias (I). It has been widely used in patients whose
arrhythmias have proved refractory to conventional agents
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lowed up on long-term amiodarone therapy for 26 ± 15
months. Sixty-three patients (55%) had one or more
adverse effects attributed to amiodarone. By life-table
analysis, 40, 69 and 80% of patients had experienced an
adverse reaction after 1, 2 and 3 years of therapy, re-
spectively. Elevated hepatic enzymes (34%), subclinical
hypothyroidism (18%) and skin discoloration (13%) were
the most common adverse reactions observed. Elevation
of hepatic enzyme activities was related to higher mean
daily dose and plasma concentrations of amiodarone
whereas skin discoloration was related to accumulated
dose, but substantial overlap between doses and levels
in patients with and without tOl'icity made the clinical
utility of these findings small. Hypothyroidism occurred
with similar frequency at all doses and plasma concen-
trations. Amiodarone plasma concentrations also did not
differ betweenthe 85effectively and 29ineffectively treated
patients.
These data indicate that monitoring amiodarone Or
desethylamiodarone levels is of limited clinical value for
assessing electrophysiologic effects or for predicting sig-
nificant clinical toxicity during therapy with doses be-
tween 100 and 400 mg/day.
(J Am Coll CardioI1987;9:1148-55)
(2-17). Despite its efficacy, the optimal method for guiding
amiodarone therapy is unknown. Amiodarone has unusual
pharmacokinetic properties because of its long elimination
half-life, its tendency to accumulate in various tissue depots
and the delayed appearance of an active metabolite, dese-
thylamiodarone. Guidelines for prescribing amiodarone
therapy based on plasma concentration of the drug remain
uncertain. A systematic approach to prescribing amiodarone
based on a safe range of plasma concentrations would be
of value because amiodarone therapy has potential for pro-
ducing toxicity in many organ systems, Although data have
been published on the pharmacokinetics, adverse effects and
therapeutic efficacy of amiodarone, there are few data avail-
able specifically addressing the practical value of monitoring
amiodarone levels in routine practice.
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In this study, we attempted to correlate amiodarone and
desethylamiodarone plasma concentrations with electro-
physiologic changes in a homogeneous group of patients
with coronary disease and sustained ventricular tachyar-
rhythmias, In addition, we prospectively examined the re-
lation of drug levels to clinical toxicity and efficacy in a
larger group of patients during long-term follow-up.
Methods
Study patients and criteria. Forty consecutive patients
withcoronary arterydiseaseand sustained ventricular tachy-
arrhythmias treated with amiodarone were studied pro-
spectively to assesscorrelations between amiodarone plasma
concentrations and electrocardiographic and electrophysi-
ologic variables. The mean age for patients in the group
was 63 ± 9 (mean ± SO) years. There were 33 men and
7 women who had had 4 ± 3 episodes of either sustained
ventricular tachycardia (n = 36) or ventricular fi brillation
(n = 4) and had failed to respond to at least oneconventional
antiarrhythmic drug before initiation of amiodarone therapy.
The mean left ventricular ejection fraction was 3I ± 14%.
Our protocol for the electrophysiologic evaluation of pa-
tients with ventricular arrhythmias has been previously de-
scribed (1 8). Sixteen patients were receiving digoxin and 4
a beta-adrenergic blocking agent at constant dosage at both
the initial and follow-up electrophysiologic study. Antiar-
rhythmic drugs were withdrawn for 2:5 half-lives before the
initial study.
All patients had either sustained ventricular tachycardia
(n = 39) or ventricular fibrillation (n = I) induced at their
initial electrophysiologic study. Patients were given a load-
ing dose of amiodarone of I,200 to I ,400 mg orally for 7
to 10 days, and were then placed on a maintenance dose of
400 mg/day. All patients underwent repeat electrophysio-
logic studies after the loading period. Patients whose ar-
rhythmias were still inducible at the 7 to 10 day study also
underwent repeat electrophysiologic study after approxi-
mately I month of therapy. In patients with two electro-
physiologic studies, only the data from the second foll ow-
up study were used for analysis.
Amiodarone plasma concentrations and QTc interval
(Bazett's formula) (19) were also examined in these patients
after 6 ± 2 months of therapy. Six month QTc values in
nine patients were excluded from analysis because of con-
comitant therapy with another antiarrhythmic drug.
Clinical toxicity and efficacy. The relations between
amiodarone plasma concentration, clinical toxicity and ef-
ficacy were prospectively analyzed in 114 consecutive pa-
tients started on amiodarone therapy who were followed up
for 26 ± 15 months (range I to 53). All patients were
followed up for a minimum of 14 months unless they died
or had amiodarone therapy discontinued becauseof toxicity
or failure. This group consistedof the 40 patients described
earlier as well as 74 additional patients who were not in-
cluded in the original 40 because they either did not have
ventricular tachycardia with coronary artery disease or did
not have a baseline and follow-up electrophysiologic study
within the guidelines described. In the entire group, 89
patients were treated for ventricular arrhythmias, 18 for
atrial fibrillation or flutter and 10 for paroxysmal supraven-
tricular tachycardia; 3 patients were treated for both ven-
tricular and supraventricular arrhythmias. Thirteen patients
were receiving additional antiarrhythmic drugs during the
period of study: quinidine in eight, procainamide in three,
mexiletine in one and both mexiletine and procainamide in
another.
Follow-up data. Patients were examined in our arrhyth-
mia unit at 3 to 6 month intervals. At each visit, laboratory
work included complete blood count and determination of
serumelectrolytes, serum glutamicoxaloacetic and glutamic
pyruvic transaminase. serum thyroxine (T4 ) , triiodothyro-
nine (T j ) concentration and resin uptake and thyroid-stim-
ulating hormone. amiodarone and desethylamiodarone lev-
els (see later), an ECG and chest X-ray film. Other studies
were obtained as clinically indicated. Plasma samples were
drawn in the early afternoon (between I and 3 PM) at least
4 hours after the morning dose of amiodarone.
Evidence (~r chemical hypothyroidism was defined as a
thyroid-stimulating hormone level of 2:16 lUlml (normal 0
to 4). All patients had thyroid-stimulating hormone con-
centrations in the normal range before amiodarone. Thy-
roxine. triiodothyronine concentration and uptake were not
analyzed with respect to published normal values, because
they may be affected by amiodarone in the absence of thy-
roid dysfunction (20).
Other side effects (~famiodarone that were analyzed with
relation 10 plasma concentration were skin discoloration,
neurologic toxicity, bradyarrhythmias that required per-
manent pacing, halo vision and pulmonary toxicity, Corneal
deposits. slight skin discoloration confined to the suborbital
regions and photosensitivity were not included in this anal-
ysis because of their wide prevalence and lack of influence
on therapy. Mild gastrointestinal upset or constipation that
occurred sporadically was also not included because it usu-
ally could not be related directly to amiodarone therapy.
The amiodarone plasma concentration measured closest
in time to the onset of clinical toxicity was used for analysis.
In patients without toxicity, the amiodarone level from the
most recent follow-up visit was used for analysis.
Ineffe ctive therapy was defined as sudden cardiac death
or recurrence of symptomatic, sustained arrhythmia. The
amiodarone plasma concentration measured closest in time
to sudden cardiac death or arrhythmia recurrence was used
in our analysis. Levels were available from within 4 weeks
of the arrhythmia recurrence in all except three patients and
all patients had continued medication up to the time of
recurrence.
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Table I. Electrocardiographic and Electrophysiologic Data
Basel ine Follow-up Increase
Study (ms) Study (ms) (ms) r Value*
Sinus CL 8 14 ± 168 942 ± 146 127 ± [53 0 ,08
Interval
QTc 440 ± 41 478 ± 53 37 ± [8 -0,30
AH 96 ± 17 115 ± 24 19 ± 18 - 0,22
HV 56 ± 12 62 ± [I 6 ± II 0 ,07
VERP
600 ms 245 ± 28 284 ± 32 39 ± 33 -0,08
400 ms 221 ± 21 266 ± 33 45 ± 38 - 0 .47
VTCL 261 ± sst 338 ± 72 77 ± 59 - 0 .0 1
*Correlation coefficient of linear regression between amiodarone plasma concentration and the increase in
each electrophysiologic variable, 'One patient had ventricular fibrillation; cycle length taken as 200 ms.
CL = cycle length; VERP = ventricular effective refractory period; VT = ventricular tachycardia.
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Plasma concentration assay. Amiodaroneand desethyl-
amiodarone plasma concentrations were measured by a high
performance liquid chromatography assay developed in our
laboratory (21), The analytical method involves mixing 0.5
ml of heparinized plasma for 20 minutes with 100 J.l-I of pH
6.0 phosphate buffer and 3.0 ml of methyltertbutyl ether
containing a structural analog of amiodarone (L8040, La
Baz, Brussels, Belgium) as an internal standard. After mix-
ing and solvent evaporation, the sample is reconstituted in
1.0 ml of acetonitrite and injected at 50°C onto a reversed
phase column containing C I 8 DB (Supelco) with the effluent
monitored at 254 nm. The plot of peak area ratios versus
concentration using this assay is linear from0.5to 5.0 J.l-glml
with a reproducibility of ± 3% (21).
Data analysis. Student's t tests for paired and unpaired
data were utilized, respectively, to assess changes in elec-
trophysiologic variables and to compare patients whose ar-
rhythmias were suppressed with those whose were not. lin-
ear correlations wereexamined by the least-squaresmethod.
Comparison of amiodarone dose and drug levels of both
amiodarone and desethylamiodarone between patients with
and without toxicity and patients who were and were not
effectively treated was performed using the Wilcoxon rank
sum test and the appropriate (after variance was assessed)
Table 2. Follow-up Electrophysiologic Study
Student's t test. A probability value of < 0.05 was consid-
ered statistically significant. Data are expressed as mean ±
SO.
Results
Electrophysiologic effects of amiodarone (Tables 1 and
2). Amiodarone therapy resulted in a significant increase
in sinus cycle length, and AH, HV and QTc intervals. The
mean increase in the HV interval was small (6 ± 11 ms),
but 7 of the 40 patients had a 2::15 ms (range 15 to 28)
increase. None of these 40 patients developed second or
third degree atrioventricular block during the follow-up pe-
riod.
Mean plasma concentrations of amiodarone and des-
ethylamiodarone at the timeof the second electrophysiologic
study were 1.39 ± 1.16 and 0. 84 ± 0.27 J.l-g/ml, respec-
tively. The sum and quotient of amiodarone and desethyl-
amiodarone plasma concentrations were 2.23 ± 1.27 and
1.72 ± 1.85 J.l-g/ml, respectively.
Linear regression analysis revealed no signifi cant cor-
relation between changes in the seven electrophysiologic
variables and amiodarone plasma concentrations at the time
of study (Table 1 and Fig. I ). Similarly, no significant
Plasma concentration (JLg/ml)
Amiodarone
DEA
Amiodarone therapy (days)
Daily dose (mg)
QTc (ms)
AVERP at400 ms
VT Induced
(n = 31)
1040 ± 1.28
0.84 :!: 0 .29
3 1 :!: 15
776 ± 30 1
41 ± 63
42 ± 29
No VT Induced
(n = 9)
1.37 ::': 0.63
0 .83 ::': 0 . 16
24 ± 14
825 ± 357
25 ± 24
44 ± 31
p Value
NS
NS
NS
NS
NS
NS
DEA = plasma concentration of desethylamiodarone; A increase in selected variable from baseline
electrophysiologic study to follow-up study; other abbrev iations as in Table I.
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Figure l. A, Comparison of the increase in right ventricular ef-
fective refractory period (IlVERP) (at 400 msdrive) from baseline
to I month follow-up study with amiodaroneplasmaconcentration
([AJ). Two points at the same location on the graph are indicated
by an asterisk. B, Comparison of the increase in ventriculartachy-
cardia (IlVT) cycle length from baseline to I month follow-up
study with amiodarone plasma concentration.
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Figure 2. Life table analysis of the probability of experiencing
one or more adverse reactions during long-term amiodarone ther-
apy.
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correlation was noted between daily dose and plasma con-
centration by linear regression analysis, only 17% of the
variability in plasma concentration was accounted for by
dosage alone, suggesting a high degree of interpatient var-
iability. One or more adverse reactions due to amiodarone
were noted in 63 (55%) of the 114 patients (Fig. 2). The
probability of a patient experiencing an adverse reaction
increased over time; it was 40% after I year, 69% after 2
years and 80% after 3 years of amiodarone therapy. An
abnormal elevation of hepatic transaminase was the most
common toxicity detected, being noted in 39 (34%) of 114
patients. Only four of these patients, however, had eleva-
tions of greater than twice the upper limits of normal and
no patient developed clinical signs of hepatic failure attrib-
utable to amiodarone. Hypothyroidism was noted in 20 pa-
tients (18%); after treatment with replacement doses of thy-
roxine, thyroid stimulating hormone levels returned to normal.
Amiodarone therapy was not discontinued because of either
hypothyroidism or abnormal tests of liver function in any
patient. Skin discoloration was noted in 15 patients. Eight
patients manifested neuromuscular toxicity (severe tremor
or muscle weakness, or both). Symptomatic bradycardia that
required implantation of a permanent pacemaker was noted
in six patients. Five patients developed complaints of halo
vision that limited their daily activities. Finally, three pa-
tients developed pulmonary infiltrates which in two resulted
in fatal complications. Amiodarone therapy was discontin-
ued only in the patients with pulmonary toxicity. Patients
with dermatologic, neurologic and ophthalmologic forms of
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relation could be identified with either desethylamiodarone
concentration or with the sum or quotient of amiodarone
and desethylamiodarone concentrations (data not shown).
In 9 (23%) of 40 patients, sustained ventricular tachy-
cardia could not be induced with programmed ventricular
stimulation at repeat electrophysiologic study. There were
no differences in mean plasma concentration, mean daily
dose or mean change in sinus cycle length, AH, HV or QTc
interval or effective refractory period between patients whose
arrhythmias were still inducible and those whose arrhyth-
mias were suppressed. Selected data from these studies are
shown in Table 2.
The relation between QTc interval and plasma concen-
trations was examined after 6 :±: 2 months of long-term
therapy. At the time of measurement the following mean
plasma concentrations were measured: amiodarone 1.99 :±:
0.99 JLg/ml, desethylamiodarone 1.46 :±: 0.29 JLg/ml and
the sum of amiodarone plus desethylamiodarone 3.44 :±:
I. 16 p,g/ml. These three concentration measures signifi-
cantly increased from 1 to 6 months of therapy (p S 0.02).
However, the QTc interval did not significantly change from
I to 6 months and there was no significant correlation be-
tween change in QTc interval from baseline and any plasma
concentration measurement.
Toxicity. The mean daily dose of amiodarone for all
114 patients was 338 :±: 108 mg/day. Although a significant
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toxicity were managed by empiric attempts at dosage re-
duction. In these patients, dosage reduction limited the pro-
gression of the adverse reaction even though complete relief
was seldom seen.
Correlations of dose, drug levels and toxicity (Table
3). There were significant correlations between amiodarone
dose and amiodarone and desethylamiodarone plasma con-
centrations and some measures of toxicity. Statistical sig-
nificance was achieved for the occurrence of abnorrnalliver
function tests and for all forms of toxicity combined. Plasma
concentrations of amiodarone tended to be higher in patients
with skin discoloration but this did not achieve statistical
significance (p == 0.08). Accumulated doses of amiodarone
were, however, significantly higher in patients developing
skin discoloration. The prevalence of the other forms of
toxicity was too low to permit individual analysis. When
all adverse reactions were considered, however, significant
correlations between amiodarone plasma level and daily
dose were observed as was a less marked correlation with
desethlyamiodarone plasma concentration.
Although mean data gave significant correlations be-
tween higher plasma concentrations and doses, the differ-
ences between means were relatively small. For clinical
purposes, it would be valuable if a clear-cut distinction could
be made between plasma concentrations associated with a
high probability of toxicity and those at which toxicity is
uncommon. However, this is not the situation for amio-
darone (Fig. 3). For each individual type of adverse reaction,
plasma levels in patients with the adverse reaction are dis-
tributed in a manner not clearly distinct from the distribution
in patients without that toxicity.
Arrhythmia recurrence. Data on plasma concentra-
tions and antiarrhythmic efficacy are listed in Table 4. Eight
(29%) of the 28 patients who were treated for supraven-
tricular arrhythmias had recurrent episodes during therapy.
There were no significant differences between effectively
and ineffectively treated patients with regard to mean amio-
darone plasma concentration (1.3 ± 0.9 versus 1.3 ± 1.0
JLg/ml) , mean desethylamiodarone plasma concentration
(1.0 ± 0.3 versus 1.0 ± 0.6 JLg/ml) or mean amiodarone
Table 3. Adverse Reactions to Amiodarone
daily dosage (247 ± 89 versus 263 ± 122 mg/day). Similar
data were observed in the group of 89 patients who were
treated for ventricular arrhythmias. Twenty-one (22%) of
89 patients had recurrent ventricular tachycardia or cardiac
arrest during amiodarone therapy. Comparison of values
between the effectively and ineffectively treated patients
showed no differences in either mean amiodarone plasma
concentration (1.9 ± 1.0 versus 1.8 ± 1.0 JLg/ml), mean
desethylamiodarone plasma concentration (1.5 ± 0.5 versus
1.4 ± 0.6 JLg/ml) or mean daily dose (357 ± 97 versus
360 ± 105 mg/day).
Discussion
Most antiarrhythmic drugs produce therapeutic and toxic
effects that are nearly proportional to their plasma concen-
trations. The frequent concentration-related side effects as-
sociated with therapy and the well described interindividual
differences in drug pharmacokinetics have made careful
monitoring of plasma concentrations a fundamental proce-
dure for prescription of drug therapy for cardiac arrhyth-
mias. Our data, however, demonstrate that, in contrast to
the usual situation with most other antiarrhythmic agents,
plasma concentrations of amiodarone and its active metab-
olite within the ranges observed in this study are not a useful
guide to the eiectrophysiologic, therapeutic or toxic effects
of the drug during long-term therapy.
Correlation of drug levels with electrophysiologic ef-
fects. Our data show that after I month of treatment, amio-
darone produces a significant increase in sinus cycle length,
QTc, AH and HV intervals, ventricular effective refractory
period and ventricular tachycardia cycle length (Table I).
These data are similar to findings reported by others (10,19,22-
25). However, despite these clear indications of amioda-
rone 's electrophysiologic effect, we found no correlation
between either drug level or drug dose and any electro-
physiologic effect measured.
The induction of ventricular tachycardia at repeat elec-
trophysiologic study was suppressed in 23% of patients after
I month of amiodarone. Again, neither drug levels, dosages
Abnormal liver
function tests
Hypothyroidism
Skin discoloration
Any toxicity
No. of
Patients
39 (±)
75 (-)
20 (+)
94 (-)
15 (+)
99 (-)
63 (±)
51 (-)
Amiodarone
(J.tg/ml)
2.08 ± 1.0*
1.64 ± 1.0
1.89 ± 1.1
1.74 ± 1.0
2.19 ± 1.0
1.71 ± 1.0
I. 96 ± LOt
1.47 ± 0.9
DEA
(J.tg/ml)
1.49 ± 0.7
1.31 ± 0.5
1.51 ± 0.6
1.34 ± 0.5
1.54 ± 0.5
1.34 ± 0.5
1.43 ± 0.6*
1.24 ± 0.5
Dose
(rug/day)
364 ± 87*
326 ± 109
368 ± 85
322 ± 106
362 ± 87
335 ± 106
367 ± 94*
292 ± 102
*p oS 0.05; tp oS O.OJ; :j:p oS 0.005. DEA = desethylamiodarone.
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Figure 3. Plasma amiodarone concentrations and occurrence for
five common adverse reactions. Plasma levels in patients with an
adverse reaction are plotted next to a bar showing the mean ± I
SD of the plasma levels in patients without that adverse effect.
Abn LFf = abnormalliverfunctiontests;PulmInfil = pulmonary
infiltrates.
nor electrophysiologic effects distinguished between pa-
tients with inducible and noninducible arrhythmias during
amiodarone therapy. Several earlier studies have also ad-
dressed these issues, Haffajee et al. (17) found no difference
in drug levels, QTc interval or refractory period between
patients with inducible and noninducible arrhythmias after
21 month of therapy. A recent prospective study of 100
patients ( II) also demonstrated no difference in amiodarone
dose or plasma concentration in the 20% of patients whose
arrhythmias were noninducible after approximately 12 weeks
of therapy. Our data are in agreement with these studies
and also show that inclusion of levels of desethylamiodarone
in the analysis is not beneficial.
Invasive electrophysiologic data were available only after
the first month of therapy. However, we found that an in-
crease in amiodarone levels after I month of therapy was
not associated with a change in the corrected QT intervals,
In contrast, Debbas et al. (26) described a high correlation
between percent increase in QTc interval and amiodarone
Table 4. Arrhythmia Recurrence During Amiodarone Therapy
No. of DEA Dose
Arrhythmia Patients Amiodarone (p,g/ml) (mg/day)
Supraventricular
Recurrence 8 1.3± 1.0 1.0 ± 0.6 263 ± 122
No recurrence 20 1.4±0.9 1.0 ± 0.3 247 ± 89
Ventricular
Recurrence 21 1.8 ± 1.0 1.4 ± 0.6 360 ± 105
No recurrence 68 1.9 ± 1.0 1.6 ± 0.5 357 ± 97
Abbreviation as in Table 3.
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level after 9 to 12 months of therapy in nine patients. Their
study, however, had a small sample size and very low mean
amiodarone concentration (0.37 JLg/ml).
Plasma concentrations and toxicity. Our data show
that, although a statistically significant correlation between
both higher plasma concentrations and higher dosages and
toxicity can be identified, this observation is of little value
for guiding prescription of individual therapy. For every
adverse reaction studied, patients with toxicity frequently
had plasma concentrations near the middle range of con-
centrations seen in patients free of toxicity.
Earlier studies (2,3,13,22) proposed that maintenance of
dosages of <600 mg/day and plasma concentrations of <2.5
JLg/ml would prevent or limit toxicity due to amiodarone.
However, these studies included a significant number of
patients treated with doses of >400 mg/day; 100% and 24%
in the studies of Greene et al. (2) and Rotmensch et al. (22),
respectively. In our study, we used lower doses of amio-
darone and only three patients, each of whom had had a
clinical failure at a lower dose, received >400 mg/day. Our
duration of follow-up was, however, greater than that in the
earlier studies. Because a dose of 400 mg/day is usually the
highest maintenance dose chosen for most patients, data on
plasma levels obtained in patients treated with higher doses
may not be relevant to optimization of therapy for most
patients. The present study shows that even with doses of
$400 rug/day, amiodarone toxicity is common and plasma
level monitoring is of little value in preventing toxicity.
Most of the side effects of amiodarone we observed were
not life-threatening. Although more serious reactions have
been described (27,28), in this series liver function test
abnormalities were usually transient or mild. Hypothyroid-
ism and bradycardia were easily managed once identified.
Skin discoloration was chiefly a cosmetic problem. Only
the development of pulmonary infiltrates was associated
with fatality. Thus, although amiodarone therapy is asso-
ciated with a significant incidence of toxicity, use of the
drug may still be justified in patients with particularly re-
sistant arrhythmias. Careful clinical follow-up and screening
for toxicity are necessary, however, because plasma level
monitoring alone does not appear to help prevent toxicity.
Plasma concentration and efficacy. Amiodarone was
an effective drug, either alone or in combination with a
second drug, for treating 71% and 78% of our patients with
supraventricular and ventricular arrhythmia, respectively.
Once again, plasma concentrations were not helpful for
prescription of therapy; levels of both amiodarone and de-
sethylamiodarone were similar in responders and nonre-
sponders. Thus, our data on both electrophysiologic effects
and efficacy indicate that each patient's dose must be guided
by clinical response and that no "therapeutic range" of safe
yet effective plasma concentrations may currently be de-
scribed.
These conclusions are similar to those of several other
studies (16, 17). However, Rotmensch et al. (22) did observe
lower drug concentrations in 9 ineffectively treated patients
than in 76 effectively treated patients. The reason for this
difference is not certain but our longer duration of therapy
may be responsible. Mostow et al. (29) also reported that
plasma concentration monitoring may be used to guide ef-
fective drug treatment but their study was conducted during
the acute phase of drug loading, and the elimination of
spontaneous ventricular ectopic activity, rather than
suppression of sustained arrhythmias, was the variable as-
sessed.
Limitations of the study. We followed a standard pro-
tocol for initiating therapy with amiodarone but differences
in individual response led to variable long-term doses. Thus,
our conclusion that plasma level data are not clinically help-
ful may be strictly justified only using our initial protocol
and within the range of long-term plasma concentrations of
amiodarone and desethylamiodarone.
Because amiodarone is >90% protein bound in plasma
(30), small changes in protein binding could theoretically
account for significant differences in electrophysiologic ef-
fect, despite similar amiodarone plasma concentrations. It
may therefore be possible to demonstrate meaningful cor-
relations if free drug levels were analyzed. Further studies
will be required to test this hypothesis.
Conclusions. Amiodarone is a powerful antiarrhythmic
drug with efficacy in many patients whose arrhythmias are
resistant to other antiarrhythmic agents. Its use, however,
is associated with a significant incidence of toxicity. Unlike
most other antiarrhythmic drugs, routine monitoring of plasma
concentrations of amiodarone or desethylamiodarone is of
little value for guiding long-term treatment either as a mea-
sure of electrophysiologic effect or as a means of preventing
toxicity.
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